Peptides: The Data Gap Behind the Hype

The six peptides at the center of the current regulatory storm, including BPC-157 and TB-500, have zero FDA approval for safety or efficacy in human trials. This is the critical data point that often gets lost in the wellness hype. As of November 2026, these compounds are not drugs in the traditional regulatory sense because they have never completed the rigorous clinical testing required to prove they do what proponents claim.

Despite this lack of evidence, access is expanding rapidly. The Department of Health and Human Services recently released a draft policy that allows licensed pharmacies to compound these substances. This move bypasses the standard FDA approval process and relies on what is known as enforcement discretion. For anyone asking about peptides, the most important fact is not that they are becoming easier to get, but that we still do not have the data to say they are safe or effective.

The Enforcement Discretion Shift

The mechanism allowing this access is technically called enforcement discretion. According to Edgar J. Asebey, a partner at the Frier Levitt law firm who leads the FDA Practice Group, this means the FDA will not enforce the prohibition against compounding these specific peptides. It is a legal loophole that is typically reserved for emergencies, such as drug shortages, rather than as a permanent market strategy.

Asebey notes that this approach was previously used when GLP-1 medications like Ozempic and Wegovy were in short supply. Pharmacies were allowed to compound exact copies to keep patients treated. Now, HHS is applying this same emergency logic to peptides that have never been approved for any condition. This is a fundamental shift in how the agency handles unproven biologics. It moves the burden of safety from the regulator to the consumer and the prescriber.

FDA Scientists Push Back

The scientific community at the FDA was not on board with this change. Reports from the Associated Press indicate that FDA scientists had little say in the latest draft policy and largely oppose it. Their primary concern is the lack of comprehensive human trials. These compounds were placed on the FDA’s do not compound list under the previous administration specifically because of serious safety concerns and the absence of robust data.

Robert F. Kennedy Jr., the HHS secretary, announced his intention to loosen these restrictions in February 2026. He stated in an interview that he believed the ban was a mistake and that the peptides should never have been restricted in the first place. Kennedy called himself a big fan of peptides and argued that the ban created a black market. His administration has now moved to formalize access through the enforcement discretion policy, effectively overriding the scientific caution of the agency he oversees.

The Wolverine Stack and Beyond

The specific compounds gaining attention include BPC-157, TB-500, and MOTS-C. BPC-157 and TB-500 are often referred to as the Wolverine stack because of their reported regenerative properties. Proponents claim they can accelerate healing and repair tissues. However, these claims are based on anecdotal evidence and limited preclinical studies, not on controlled human trials that would meet the standard for medical proof.

MOTS-C is another peptide in this group that is gaining traction in longevity circles. It is often promoted for its potential effects on metabolic health and muscle preservation. Like the others, it lacks the clinical data required for FDA approval. The inclusion of these three in the new access policy signals a broader push to allow a wider range of unproven peptides to enter the mainstream market through licensed pharmacies.

Clinical Monitoring and New Models

Some companies are trying to bring order to this chaotic landscape. Superpower, a health company based in San Francisco, launched its own peptide program on November 2, 2026. Their approach is to pair prescription peptide care with comprehensive blood testing and ongoing clinical support. This is a direct response to the lack of guidelines in the market.

Max Marchione, the CEO of Superpower, stated that they are rebuilding healthcare rather than just iterating on it. The company integrates AI to identify personalized insights and connects patients with licensed clinicians. By monitoring baseline bloodwork and tracking health throughout treatment, they aim to provide the context that makes peptide use meaningful. This model attempts to mitigate some of the risks associated with unregulated access by keeping the process under clinical supervision.

Red Flags in the Data

One of the most persistent myths is that peptides are not drugs. Gary Brecka, a co-chair of the MAHA Action committee, has argued this point on his podcast. However, legal and medical experts disagree. Jacob Sherkow, a professor of law at the University of Illinois Urbana-Champaign, points out that if a substance is used to treat, prevent, or cure conditions, it is a drug by definition. Insulin is a peptide, and it is a drug when injected to regulate blood sugar.

The FDA panel that voted to loosen restrictions included members with financial stakes in the peptide industry. Haleem Mohammed, the chief medical officer of a men’s clinic that sells peptides, voted in favor of the change. He cited patient safety and medical freedom as his reasons. HHS spokesperson Emily Hilliard stated that all committee members satisfy the agency’s ethics requirements. This conflict of interest raises serious questions about the objectivity of the decision to remove these compounds from the do not compound list.